Is Sermorelin FDA Approved? Regulatory History and Current Status

Sermorelin occupies an unusual position in the regulatory history of growth hormone-axis peptides: it is one of the only synthetic GHRH analogues to have received FDA approval, yet that approval was withdrawn from the US market more than fifteen years ago. Understanding this history — what was approved, under what indication, and why the product was discontinued — is essential context for researchers and clinicians working with GHRH analogue data today.

Research reference only. All information on this page summarises publicly available regulatory history and peer-reviewed literature. It does not constitute medical or legal advice.

Sermorelin's original FDA approval

Sermorelin (chemical name: sermorelin acetate; INN: sermorelin) is the synthetic acetate salt of GHRH(1-29)NH₂ — the first 29 amino acids of the 44-amino-acid endogenous growth hormone-releasing hormone. It was developed and commercialised by Serono Laboratories under the brand name Geref.

The FDA approved sermorelin (Geref) under two distinct indications:

Diagnostic use — growth hormone deficiency (GHD) testing in children: Sermorelin served as a pharmacological stimulus in the sermorelin stimulation test, an alternative to insulin tolerance testing (ITT) for assessing pituitary somatotroph reserve. A single intravenous dose of sermorelin was administered, and peak serum GH response below a defined threshold was used to confirm GHD.
Therapeutic use — idiopathic GHD treatment in children: Geref Diagnostic and Geref were separately approved for treatment of children with idiopathic growth hormone deficiency, representing one of the few occasions a GHRH analogue received an FDA therapeutic indication.

The sermorelin approval predated the widespread availability of recombinant human growth hormone (rhGH) as the standard of care for GHD. As rhGH products became more accessible and better characterised, the clinical landscape shifted substantially.

Why sermorelin was withdrawn from the US market

Serono voluntarily withdrew Geref from the US market in 2008. The withdrawal was categorised as commercial — not the result of safety signals, regulatory enforcement, or a required post-market study failure. In the FDA's product withdrawal database, sermorelin is listed as a voluntary market withdrawal without a safety-based rationale.

The commercial rationale is widely understood to reflect the competitive pressure from rhGH products: once recombinant GH became the standard diagnostic and therapeutic tool for GHD in children, the market for a GHRH analogue was substantially reduced. The infrastructure required to maintain a licensed pharmaceutical product — ongoing stability testing, post-market surveillance, and distribution — was no longer economically justified for the remaining market segment.

Sermorelin is not currently FDA-approved for any indication. The voluntary withdrawal of Geref means there is no approved sermorelin product in the United States as of 2026. This is a critical distinction for researchers citing sermorelin's regulatory history: historical approval does not equal current approval.

Sermorelin under the 503A compounding framework

Following the market withdrawal, sermorelin became available through US compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. 503A permits patient-specific compounding from bulk drug substances for individual prescriptions when specific conditions are met.

However, sermorelin's status under 503A has been subject to ongoing FDA review:

The FDA's Pharmacy Compounding Advisory Committee (PCAC) has evaluated peptides for inclusion on the 503A "bulk drug substance" list that permits lawful compounding.
As of the date of this article, sermorelin's compounding status is classified as Under Review — it has not been placed on the positive list (Category 1) that would explicitly permit routine 503A compounding, nor has it been placed on the Category 2 list of substances that would restrict it.
The July 2026 PCAC meeting is reviewing several peptides; researchers and clinicians should verify current 503A status directly with the FDA PCAC register at the time of protocol design, as this classification can change.

How sermorelin compares to other approved GHRH analogues

Among GHRH analogues currently or historically available in the US, sermorelin's regulatory history is distinct:

Tesamorelin (Egrifta): Tesamorelin is an FDA-approved GHRH analogue with an active label as of 2026. Approved in 2010 for reduction of excess abdominal fat in HIV-associated lipodystrophy, tesamorelin represents the only GHRH analogue with a current FDA approval for a therapeutic indication. Its approval was based on Phase III clinical trial evidence in a specific HIV/ARV-treated population, not the general GHD population targeted by sermorelin.

CJC-1295 (with or without DAC): CJC-1295 and its drug affinity complex (DAC) variant have no regulatory approval in any jurisdiction and are classified as research compounds. They differ from sermorelin in half-life (CJC-1295 without DAC: ~30 min; with DAC: ~6–8 days) due to DPP-IV-resistance modifications and, for the DAC form, covalent albumin binding.

Sermorelin vs. tesamorelin in research: The practical research implication is that sermorelin data, where generated in approved Geref-era clinical programs, provides one of the better-characterised safety and pharmacokinetic reference datasets for GHRH(1-29) analogues. Researchers designing protocols involving GHRH-axis peptides often reference sermorelin stimulation-test literature for baseline GH pulse amplitude and GHRH receptor pharmacodynamics, even though sermorelin itself is no longer a licensed product.

Current research and clinical context

Clinical use of sermorelin in the US today occurs primarily through 503A compounding pharmacies, pending the outcome of the PCAC review. Researchers encountering sermorelin in the literature should note that most published data were generated under the Geref indication — pediatric GHD diagnosis and treatment — and represent a controlled-dosing, physician-administered context rather than the adult wellness or anti-aging protocols sometimes discussed in non-peer-reviewed contexts.

The distinction between historical FDA approval and current regulatory status matters for interpreting published evidence. Sermorelin was tested, characterised, and approved in a specific population under a specific indication; extrapolating those safety and efficacy data to other populations or endpoints requires independent justification from the published literature.

Frequently Asked Questions

Is sermorelin currently FDA approved?

No. Sermorelin received FDA approval under the brand name Geref for two pediatric indications — GH deficiency diagnosis and treatment — but the manufacturer voluntarily withdrew the product from the US market in 2008 for commercial reasons. No FDA-approved sermorelin product exists in the US as of 2026.

Why was sermorelin taken off the market?

Sermorelin (Geref) was voluntarily withdrawn by Serono in 2008 for commercial, not safety, reasons. The withdrawal is listed in FDA records as a voluntary market withdrawal without a safety-based rationale. The competitive pressure from recombinant human growth hormone (rhGH) products, which became the standard of care for GHD, substantially reduced demand for a GHRH analogue diagnostic and therapeutic.

Can sermorelin be prescribed in the US today?

Sermorelin is available through 503A compounding pharmacies in the US under patient-specific prescriptions, subject to ongoing FDA regulatory review of its compounding status. It is not available as an FDA-approved branded pharmaceutical. Clinicians and researchers should verify current 503A status directly with the FDA Pharmacy Compounding Advisory Committee register, as the classification is subject to change.

How does sermorelin differ from tesamorelin?

Tesamorelin (Egrifta) is an FDA-approved GHRH analogue with a current therapeutic indication for HIV-associated lipodystrophy as of 2026; sermorelin has no current FDA approval after its 2008 withdrawal. Structurally, tesamorelin is a modified GHRH(1-44) analogue with a trans-3-hexenoic acid group at the N-terminus that confers greater DPP-IV stability and a longer effective half-life than sermorelin's GHRH(1-29) backbone. Both activate the GHRH receptor (GHRH-R) on pituitary somatotroph cells, but their structural differences, half-life profiles, and regulatory histories make them pharmacologically distinct for research protocol purposes.

What was the sermorelin stimulation test?

The sermorelin stimulation test was a pharmacological pituitary challenge used to diagnose growth hormone deficiency in children. A single intravenous dose of sermorelin (GHRH[1-29]NH₂) was administered, and serum GH was measured at intervals over 60–120 minutes. A peak GH response below a defined threshold (typically 7–10 ng/mL, depending on assay and protocol) indicated impaired somatotroph reserve consistent with GHD. The test was an alternative to the insulin tolerance test (ITT), which requires hypoglycemia induction and carries cardiovascular contraindications. Following Geref's market withdrawal, the sermorelin stimulation test is no longer conducted in standard clinical practice in the US, and alternative GHRH-arginine or GHRH-GHRP stimulation protocols using other agents have been described in the endocrinology literature.

Regulatory status information is current as of May 2026. Compounding classification can change without notice; verify current FDA PCAC status at fda.gov before designing protocols involving compounded sermorelin.